Additional Information

Description

Orencia (abatacept) is a selective T-cell costimulation modulator indicated for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). Orencia can be administered alone or in combination with non-biologic DMARDs but should not be used with Janus kinase (JAK) inhibitors or biologic DMARDs, such as tumor necrosis factor (TNF) antagonists.

Orencia is also approved for the treatment of moderate to severe polyarticular juvenile idiopathic arthritis (pJIA) in patients aged two years and older. It may be used as monotherapy or in combination with methotrexate (MTX). By targeting immune system dysregulation, Orencia helps manage joint inflammation, prevent disease progression, and improve overall physical function in pediatric patients.

For patients with active psoriatic arthritis (PsA), Orencia reduces signs and symptoms of the disease and prevents structural joint damage. It is approved for use in adults either as monotherapy or in combination with non-biologic DMARDs. In pediatric patients, it may be used alone or with MTX to control inflammation and minimize disease progression.